Antengene wins China CDE endorsement for Phase III ATG-022 gastric cancer trial
PUBT · 2d ago
Share
Listen to the news
- China’s NMPA drug review center endorsed Antengene’s pivotal Phase III CLINCH-3 trial of CLDN18.2 ADC ATG-022 in advanced gastric or GEJ cancer.
- Trial to start in China first, designed to support a future marketing application for ATG-022 monotherapy.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Antengene Corporation Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605272000PR_NEWS_USPR_____CN68880) on May 28, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending